MALRD1
MAM and LDL-receptor class A domain-containing protein 1
Protein Summary
Enhances production and/or transport of FGF19 and thus has a role in regulation of bile acid synthesis. This gene encodes a conserved protein that features multiple MAM (meprin-A5-protein tyrosine phosphatase mu) and LDLR A2 (low density lipoprotein receptor A2) domains. Expression of this gene is enriched in the small intestine and is upregulated during differentiation of a human cell line that exhibits properties of intestinal epithelial cells. The encoded protein has been shown to modulate production of FGF19 in a human intestinal cell line and may regulate bile acid metabolism in the liver. A synergistic interaction between an allele of this gene and the APOE E4 allele is associated with an elevated risk of Alzheimer's disease in human patients. [provided by RefSeq, Jul 2017]
- ENST00000454679
- ENSP00000412763
- ENSG00000204740
- C10orf112
- DIET1
- DIET1
- C10orf112
- bA265G8.2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
trait | 0.99 | ||
tissue sample | 0.84 | ||
tissue | 0.68 | ||
disease | 0.55 | ||
phenotype | 0.54 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 22.93 (req: < 5)
Gene RIFs: 5 (req: <= 3)
Antibodies: 13 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 22.93 (req: >= 5)
Gene RIFs: 5 (req: > 3)
Antibodies: 13 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 2
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0